The estimated Net Worth of Jonathan Biller is at least $4.93 Миллион dollars as of 9 February 2024. Mr. Biller owns over 1,738 units of Agios Pharmaceuticals Inc stock worth over $809,987 and over the last 6 years he sold AGIO stock worth over $939,346. In addition, he makes $3,183,890 as Chief Financial Officer и Head of Legal and Corporate Affairs at Agios Pharmaceuticals Inc.
Sign up
Mr. Biller AGIO stock SEC Form 4 insiders trading
Jonathan has made over 12 trades of the Agios Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,738 units of AGIO stock worth $727,822 on 9 February 2024.
The largest trade he's ever made was exercising 8,523 units of Agios Pharmaceuticals Inc stock on 18 February 2022 worth over $377,654. On average, Jonathan trades about 1,859 units every 78 days since 2018. As of 9 February 2024 he still owns at least 18,280 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Mr. Biller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jonathan Biller biography
Jonathan Prim Biller serves as Chief Financial Officer, Head of Legal and Corporate Affairs of the Company. He has more than 30 years of legal, tax and treasury experience. Prior to joining Agios, Mr. Biller held leadership roles at Celgene, leading Celgene’s global legal function as executive vice president and general counsel from July 2018 to November 2019, and serving as senior vice president, tax and treasury from 2011 to June 2018, in which role he was responsible for the company’s global tax and treasury functions including its capital allocation strategy and tax policy. Prior to Celgene, Mr. Biller was general counsel, chief tax officer and secretary for Bunge. Prior to Bunge, Mr. Biller held roles of increasing responsibility at Alcon, Inc., during which time it was a publicly traded company. Mr. Biller began his career at law firm Hopkins & Sutter rising to the level of partner and was also partner at Foley & Lardner LLP after the firms merged. Mr. Biller also serves on the Board of Junior Achievement New Jersey. He holds a B.A. from Brown University and a J.D. from Yale Law School.
What is the salary of Jonathan Biller?
As the Chief Financial Officer и Head of Legal and Corporate Affairs of Agios Pharmaceuticals Inc, the total compensation of Jonathan Biller at Agios Pharmaceuticals Inc is $3,183,890. There are 2 executives at Agios Pharmaceuticals Inc getting paid more, with Jacqualyn Fouse having the highest compensation of $16,608,000.
How old is Jonathan Biller?
Jonathan Biller is 57, he's been the Chief Financial Officer и Head of Legal and Corporate Affairs of Agios Pharmaceuticals Inc since 2020. There are 17 older and 5 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.
What's Jonathan Biller's mailing address?
Jonathan's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Insiders trading at Agios Pharmaceuticals Inc
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen и John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
What does Agios Pharmaceuticals Inc do?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
What does Agios Pharmaceuticals Inc's logo look like?
Complete history of Mr. Biller stock trades at Agios Pharmaceuticals Inc и Vertex Pharmaceuticals
Agios Pharmaceuticals Inc executives and stock owners
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jacqualyn Fouse,
Chief Executive Officer, Director -
Christopher Bowden,
Chief Medical Officer -
Jonathan Biller,
Chief Financial Officer, Head of Legal and Corporate Affairs -
David Schenkein,
Executive Chairman of the Board -
Dr. Sarah Gheuens M.D., Ph.D.,
Chief Medical Officer -
Dr. Jacqualyn A. Fouse,
CEO & Director -
Dr. Bruce Car Ph.D.,
Chief Scientific Officer -
Jonathan Biller J.D.,
CFO & Head of Corp. Affairs -
Richa Poddar,
Chief Commercial Officer -
John Maraganore,
Independent Director -
Kaye Foster,
Independent Director -
Paul Clancy,
Independent Director -
Maykin Ho,
Independent Director -
David Scadden,
Director -
Ian Clark,
Independent Director -
Holly Manning,
IR Contact Officer -
Bruce Car,
Chief Scientific Officer -
Dr. Craig B. Thompson M.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Kendra Adams,
VP of External Communications & Investor Relations -
Dr. Clive Patience Ph.D.,
Chief Technical Operations Officer -
T. J. Washburn Jr.,
Principal Accounting Officer -
Dr. Shin-San Su Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Craig B. Thompson,
Co-Founder & Chairman of Scientific Advisory Board -
Dr. Tak Wah Mak,
Co-Founder & Member of Scientific Advisory Board -
Dr. Lewis Clayton Cantley Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Lewis Clayton Jr. Cantley,
Director -
Carman Alenson,
Principal Accounting Officer -
Scott Biller,
Chief Scientific Officer -
Douglas G. Cole,
Director -
Steven L. Hoerter,
Chief Commercial Officer -
Marc Tessier Lavigne,
Director -
Robert Nelsen,
Director -
European Investment Co Llc ...,
-
Corp /De/Celgene Switzerlan...,
-
Sarah Gheuens,
Chief Medical Officer -
Ventures Fund 2007, L.P.Afe...,
-
Venture Fund Vii Lparch Ven...,
-
European Investment Co Llc ...,
10% owner -
European Investment Co Llcc...,
-
Rock Ventures Lp Third Rock...,
-
Kevin P Starr,
Director -
Glenn Goddard,
Senior Vice President, Finance -
John Duncan Higgons,
Chief Operating Officer -
Venture Fund Vii Lparch Ven...,
-
Perry A Karsen,
Director -
Corp /De/Celgene European I...,
-
Catherine E. Owen,
Director -
Cecilia Jones,
Chief Financial Officer -
Theodore James Jr. Washburn,
Principal Accounting Officer -
Darrin Miles,
Chief Commercial Officer -
Richa Poddar,
Chief Commercial Officer -
James William Burns,
Chief Legal Officer -
Brian Goff,
Chief Executive Officer -
Rahul D. Ballal,
Director -
Cynthia Smith,
Director -
Tsveta Milanova,
Chief Commercial Officer -
Jeffrey D Capello,
Director